These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35316843)

  • 1. Antibiotic Management of Patients with Hematologic Malignancies: From Prophylaxis to Unusual Infections.
    Moreno-Sanchez F; Gomez-Gomez B
    Curr Oncol Rep; 2022 Jul; 24(7):835-842. PubMed ID: 35316843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of daptomycin in the treatment of infections in patients with hematological malignancies].
    Salavert M; Calabuig E
    Med Clin (Barc); 2010 Dec; 135 Suppl 3():36-47. PubMed ID: 21477703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging of Hematological Patients in the Era of COVID-19.
    Eshet Y; Avigdor A; Kedmi M; Tau N
    Acta Haematol; 2022; 145(3):267-274. PubMed ID: 35100592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies.
    Chong Y; Yakushiji H; Ito Y; Kamimura T
    Int J Infect Dis; 2011 Apr; 15(4):e277-81. PubMed ID: 21324723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Counterpoint: routine anti-bacterial prophylaxis is not indicated in neutropenic patients with hematological malignancies.
    Kleinberg M
    J Natl Compr Canc Netw; 2004 Sep; 2(5):445-51. PubMed ID: 19780253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode.
    Demirel A; Tabak F; Ar MC; Mete B; Öngören Ş; Yemişen M; Özaras R; Eşkazan E; Başlar Z; Mert A; Soysal T; Ferhanoğlu B; Aydın Y; Öztürk R
    Turk J Haematol; 2015 Sep; 32(3):243-50. PubMed ID: 25913035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Febrile neutropenia in hematologic malignancies.
    Keng MK; Sekeres MA
    Curr Hematol Malig Rep; 2013 Dec; 8(4):370-8. PubMed ID: 23990311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 in hematological malignancies: Case series and literature review.
    Ocheni S; Nwagha TU; Amu N; Obodo OI; Okereke K; Chikezie K; Ejezie CS; Ilechukwu GU; Obiatuegwu C
    Ann Afr Med; 2023; 22(3):381-384. PubMed ID: 37417029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infections of febrile neutropenic patients in malignant hematological diseases.
    Rókusz L; Liptay L
    Mil Med; 2003 May; 168(5):355-9. PubMed ID: 12775168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
    Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
    Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Approaches for Managing Patients with Hematological Malignancies in the Time of COVID-19 Pandemic.
    Seval GC; Topçuoğlu P; Demirer T
    Turk J Med Sci; 2021 Dec; 51(6):2799-2809. PubMed ID: 33705648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis and treatment of bacterial infections: do we need new strategies?
    Micozzi A; Bucaneve G
    Rev Clin Exp Hematol; 2005 Dec; 9(2):E4. PubMed ID: 16864118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
    Baskaran ND; Gan GG; Adeeba K
    Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of imipenem 1.5 g daily in febrile patients with short duration neutropenia after chemotherapy for non-leukemic hematologic malignancies and solid tumors: personal experience and review of the literature.
    Jourdan E; Defez C; Topart D; Richard B; Bellabas H; Fabbro-Peray P; Jourdan J; Sotto A
    Leuk Lymphoma; 2003 Apr; 44(4):619-26. PubMed ID: 12769338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The management of hematologic malignancies during the COVID-19 pandemic.
    Hus I; Salomon-Perzyński A; Tomasiewicz K; Robak T
    Expert Opin Pharmacother; 2021 Apr; 22(5):565-582. PubMed ID: 33342308
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies.
    Civriz Bozdağ S; Cengiz Seval G; Yönal Hindilerden İ; Hindilerden F; Andıç N; Baydar M; Aydın Kaynar L; Toprak SK; Göksoy HS; Balık Aydın B; Demirci U; Can F; Özkocaman V; Gündüz E; Güven ZT; Özkurt ZN; Demircioğlu S; Beksaç M; İnce İ; Yılmaz U; Eroğlu Küçükdiler H; Abishov E; Yavuz B; Ataş Ü; Mutlu YG; Baş V; Özkalemkaş F; Üsküdar Teke H; Gürsoy V; Çelik S; Çiftçiler R; Yağcı M; Topçuoğlu P; Çeneli Ö; Abbasov H; Selim C; Ar MC; Yücel OK; Sadri S; Albayrak C; Demir AM; Güler N; Keklik M; Terzi H; Doğan A; Yegin ZA; Kurt Yüksel M; Sadri S; Yavaşoğlu İ; Beköz HS; Aksu T; Maral S; Erol V; Kaynar L; İlhan O; Bolaman AZ; Sevindik ÖG; Akyay A; Özcan M; Gürman G; Ünal Ş; Yavuz Y; Diz Küçükkaya R; Özsan GH
    Turk J Haematol; 2022 Feb; 39(1):43-54. PubMed ID: 34521187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing patients with hematological malignancies during COVID-19 pandemic.
    Sahu KK; Cerny J
    Expert Rev Hematol; 2020 Aug; 13(8):787-793. PubMed ID: 32580592
    [No Abstract]   [Full Text] [Related]  

  • 18. Obesity is not strongly associated with increased risk for febrile neutropenia during levofloxacin prophylaxis in patients with hematological malignancies receiving intermediate-risk myelosuppressive chemotherapy.
    Kurtti A; Fritz K; Elofson-Disney K; Benefield R
    J Oncol Pharm Pract; 2020 Sep; 26(6):1301-1305. PubMed ID: 31810423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era.
    Zerbit J; Detroit M; Meyer A; Decroocq J; Deau-Fischer B; Deschamps P; Birsen R; Mondesir J; Franchi P; Miekoutima E; Guerin C; Batista R; Bouscary D; Willems L; Vignon M
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.